Comparison of Next-Generation Sequencing Platforms for Clinical Testing of Non-Small Cell Lung Cancer
DOI:
https://doi.org/10.17140/PRRMOJ-2-116Keywords:
Adenocarcinoma, Non-small cell lung cancer, Personalized medicine, Mutational analysis, Pleural effusion, Circulating free DNA, Next generation sequencingAbstract
Personalized treatment of lung cancer using therapies that target activating oncogenic mutations such as EGFR and ALK has become the standard of care. Current molecular testing is routinely performed for single genes and increasingly in a multiplex format. However, the scarcity of sufficient biopsy material has necessitated a more high-throughput and comprehensive testing approach. Next Generation Sequencing (NGS) offers great promise as a highly sensitive method of detection for a variety of biopsy sources (tissue, blood, pleural effusions). However, there are multiple NGS platforms and panels with varying advantages and disadvan-tages. This pilot study compared four different library construction methods (Ion AmpliSeq, Illumina TruSeq, and Raindance Thunderbolts amplicon-based methods and Roche EZSeq se-quence capture method) and two different sequencing instruments (Ion Torrent PGM and Il-lumina MiSeq). A common set of ten tumor/normal pairs from lung adenocarcinoma patients were analysed by all platforms. Additional samples were analysed in subsets of the platforms. To assess the feasibility of sequencing circulating free DNA (cfDNA) from plasma and pleural effusions, two additional samples were analysed on two amplicon-based platforms. A bioin-formatic pipeline for automated sequence data analysis was developed using the Galaxy environment. To determine the most cost-effective, technically streamlined library construction and sequencing method, we compared coverage statistics, sensitivity, variant detection, and workflow for all platforms.
References
WHO. Cancer Fact Sheet 297. World Health Organization 2014.
Zhang J, Fujimoto J, Wedge DC, et al. Intratumor heteroge-neity in localized lung adenocarcinomas delineated by multi-region sequencing. Science. 2014; 346: 256-259. doi: 10.1126/ science.1256930
Seoane J, De Mattos-Arruda L. The challenge of intratumour heterogeneity in precision medicine. J Intern Med. 2014; 276: 41-51.
Elshimali YI, Khaddour H, Sarkissyan M, Wu Y, Vadgama JV. The clinical utilization of circulating cell free DNA (CCFD-NA) in blood of cancer patients. Int J Mol Sci. 2013; 14: 18925- 18958. doi: 10.3390/ijms140918925
Liu D, Lu Y, Hu Z, et al. Malignant pleural effusion superna-tants are substitutes for metastatic pleural tumor tissues in EGFR mutation test in patients with advanced lung adenocarcinoma. PLoS One. 2014; 9: e89946. doi: 10.1371/journal.pone.0089946
Hedegaard J, Thorsen K, Lund MK, et al. Next-generation sequencing of RNA and DNA isolated from paired fresh-frozen and formalin-fixed paraffin-embedded samples of human cancer and normal tissue. PLoS One. 2014; 9: e98187. doi: 10.1371/ journal.pone.0098187
Young G, Wang K, He J, et al. Clinical next-generation se-quencing successfully applied to fine-needle aspirations of pul-monary and pancreatic neoplasms. Cancer Cytopathol. 2013; 121: 688-694. doi: 10.1002/cncy.21338
Luke JJ, Oxnard GR, Paweletz CP, et al. Realizing the poten-tial of plasma genotyping in an age of genotype-directed thera-pies. J Natl Cancer Inst. 2014; 106.
Couraud S, Vaca Paniagua F, Villar S, et al. Non-invasive diagnosis of actionable mutations by deep sequencing of circulating-free DNA in non-small cell lung cancer: Find-ings from BioCAST/IFCT-1002. Clin Cancer Res. 2014. doi:
1158/1078-0432.CCR-13-3063 10. Yip L. Molecular diagnostic testing and the indeterminate thyroid nodule. Curr Opin Oncol. 2014; 26: 8-13. doi: 10.1097/ CCO.0000000000000023
Le Mercier M, D’Haene N, De Neve N, et al. Next-gener-ation sequencing improves the diagnosis of thyroid FNA speci-mens with indeterminate cytology. Histopathology. 2014. doi: 10.1111/his.12461
Simen BB, Yin L, Goswami CP, et al. Validation of a Next-Generation-Sequencing Cancer Panel for Use in the Clinical Laboratory. Arch Pathol Lab Med. 2014.
Nikiforova MN, Wald AI, Roy S, Durso MB, Nikiforov YE. Targeted next-generation sequencing panel (ThyroSeq) for de-tection of mutations in thyroid cancer. J Clin Endocrinol Metab. 2013. doi: 10.1210/jc.2013-2292
Pritchard CC, Salipante SJ, Koehler K, et al. Validation and Implementation of Targeted Capture and Sequencing for the Detection of Actionable Mutation, Copy Number Variation, and Gene Rearrangement in Clinical Cancer Specimens. J Mol Di-agn. 2013; 16: 56-67. doi: 10.1016/j.jmoldx.2013.08.004
Frampton GM, Fichtenholtz A, Otto GA, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013; 31: 1023-1031. doi: 10.1038/nbt.2696
Goecks J, Nekrutenko A, Taylor J. Galaxy: a comprehensive approach for supporting accessible, reproducible, and transpar-ent computational research in the life sciences. Genome Biol. 2010; 11: R86. doi: 10.1186/gb-2010-11-8-r86
Greer W, Morzycki W, Bethune D, Xu Z, Douglas S. Molec-ular Diagnostics for Lung Cancer in Atlantic Canada. Canadian Journal of Pathology. 2015.
Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler Transform. Bioinformatics. 2009; 25: 1754- 1760.
Van der Auwera GA, Carneiro M, Hartl C, et al. From FastQ data to high-confidence variant calls: The Genome Analysis Toolkit best practices pipeline. Curr. Prot.Bioinformatics. 2013; 43: 11.10.11-11.10.33. doi: 10.1002/0471250953.bi1110s43
Li H, Handsaker B, Wysoker A, et al. The Sequence align-ment/map (SAM) format and SAMtools. Bioinformatics. 2009; 25: 2078-2079. doi: 10.1093/bioinformatics/btp352
Koboldt DC, Chen K, Wylie T, et al. VarScan: variant detec-tion in massively parallel sequencing of individual and pooled samples. Bioinformatics. 2009; 25: 2283-2285. doi: 10.1093/ bioinformatics/btp373
Koboldt DC, Zhang Q, Larson DE, et al. VarScan 2: so-matic mutation and copy number alteration discovery in can-cer by exome sequencing. Genome Res. 2012; 22: 568-576. doi: 10.1101/gr.129684.111
Chen K, Wallis JW, McLellan MD, et al. BreakDancer: an al-gorithm for high-resolution mapping of genomic structural vari-ation. Nat Methods. 2009; 6: 677-681. doi: 10.1038/nmeth.1363
Vandeweyer G, Van Laer L, Loeys B, Van den Bulcke T, Kooy RF. Variant DB: a flexible annotation and filtering portal for next generation sequencing data. Genome Med. 2014; 6: 74. doi: 10.1186/s13073-014-0074-6
Quail MA, Smith M, Coupland P, et al. A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pa-cific Biosciences and Illumina MiSeq sequencers. BMC Genom-ics. 2012; 13: 341. doi: 10.1186/1471-2164-13-341
Oxnard GR, Paweletz CP, Kuang Y, et al. Noninvasive de-tection of response and resistance in EGFR-mutant lung can-cer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res. 2014; 20: 1698-1705. doi: 10.1158/1078-0432.CCR-13-2482
Aung KL, Donald E, Ellison G, et al. Analytical validation of BRAF mutation testing from circulating free DNA using the amplification refractory mutation testing system. J Mol Diagn. 2014; 16: 343-349. doi: 10.1016/j.jmoldx.2013.12.004
Rothe F, Laes JF, Lambrechts D, et al. Plasma circulating tumor DNA as an alternative to metastatic biopsies for muta-tional analysis in breast cancer. Ann Oncol. 2014. doi: 10.1093/ annonc/mdu288
Aziz N, Zhao Q, Bry L, et al. College of American Patholo-gists’ Laboratory Standards for Next-Generation Sequenc-ing Clinical Tests. Arch Pathol Lab Med. 2014. doi: 10.5858/ arpa.2014-0250-CP
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Pulmonary Research and Respiratory Medicine (PRRM) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
